Lauren N. Martin

Lauren N. Martin is a patent litigation attorney at Quinn Emanuel Urquhart & Sullivan, based in the firm's Boston office, where she was elected partner in December 2023. Her practice focuses primarily on patent disputes within the life sciences, encompassing biotechnology, medical devices, diagnostic testing, and chemical arts.

Ms. Martin consistently represents defendants in patent litigation, with all four of her tracked appearances being on the defense side. Her experience includes defending operating companies in complex patent infringement actions and post-grant review proceedings. She has significant experience serving as trial counsel in various courts.

Her notable case experience includes representing Halozyme Inc. as a defendant in multiple inter partes review (IPR) proceedings initiated by Unified Patents and other petitioners before the Patent Trial and Appeal Board (PTAB). Beyond IPRs, she has represented C.R. Bard in patent infringement litigation involving implantable vascular access ports, securing a jury verdict and summary judgment of non-infringement. She also represented Vifor Fresenius in Hatch-Waxman cases concerning the drug Velphoro, prevailing at trial in one instance that led to favorable settlements. Additionally, she has represented Amgen in a patent dispute involving written description and enablement challenges for an antibody patent, progressing through District Court, the Federal Circuit, and the Supreme Court.

Ms. Martin is actively involved in PTAB and IPR proceedings, frequently appearing as counsel or backup counsel for patent owners in such challenges. She is registered to practice before the U.S. Patent and Trademark Office, holding registration number 61,112.